TFA Therapeutics (RAJAF) Net Income towards Common Stockholders (2020 - 2023)

TFA Therapeutics has reported Net Income towards Common Stockholders for 4 years, with the latest figure at $57616.0 in Q4 2023.

• On a quarterly basis, Net Income towards Common Stockholders rose 116.85% year-over-year to $57616.0 in Q4 2023; TTM through Dec 2023 was -$669359.0, a N/A change from a year earlier, with the FY2021 full-year figure at $1.19, up 100.01% from the prior year.
• Net Income towards Common Stockholders was $57616.0 for Q4 2023 at TFA Therapeutics, up from -$341873.0 in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $57616.0 in Q4 2023, with the low at -$371626.0 in Q4 2021.
• Average Net Income towards Common Stockholders over 4 years is -$167339.8, with a median of -$177674.5 recorded in 2020.
• The sharpest annual moves came in 2021 and 2023: Net Income towards Common Stockholders plunged 2657.69% in 2021, then jumped 116.85% in 2023.
• Over 4 years, Net Income towards Common Stockholders stood at -$13476.0 in 2020, then slumped by 2657.69% to -$371626.0 in 2021, then grew by 8.01% to -$341873.0 in 2022, then soared by 116.85% to $57616.0 in 2023.
• The last three Net Income towards Common Stockholders figures came in at $57616.0 (Q4 2023), -$341873.0 (Q4 2022), and -$371626.0 (Q4 2021), per Business Quant data.